GLP-1 oral threat overblown for Stevanato
The bull case argued that the market's fear of GLP-1 injectables losing share to oral versions is an overreaction, as injectables remain more effective and necessary for severe cases, and the overall GLP-1 market is still in early growth.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.